GLP-1受体激动剂与2型糖尿病患者非创伤性脑出血风险
该回顾性队列研究利用TriNetX全球健康数据,比较使用与未使用GLP-1RAs的2型糖尿病患者,经倾向评分匹配后每组255 460人。结果显示GLP-1RAs使用与较低脑出血风险相关(HR 0.743,95%CI 0.684-0.807),且所有出血部位均一致,同时死亡率与缺血性卒中风险也较低。
要点
- GLP-1RAs使用与2型糖尿病患者脑出血风险降低相关(HR 0.743)。
- 该关联在所有脑出血部位均一致(所有P≤0.01)。
- GLP-1RAs还与非创伤性脑出血患者的较低死亡率和缺血性卒中风险相关。
核心结论
- GLP-1RAs使用与2型糖尿病患者较低的非创伤性脑出血风险相关。
研究设计与样本
- 回顾性队列研究,使用TriNetX全球健康数据,比较使用GLP-1RAs(n=326 777)与未使用(n=643 614)的2型糖尿病患者。
- 经1:1倾向评分匹配后形成两组各255 460人,随访长达4年。
主要发现
- 匹配后GLP-1RAs使用与较低脑出血风险相关(HR 0.743,95%CI 0.684-0.807)。
- GLP-1RAs相关的较低脑出血风险在所有出血部位均观察到(所有P≤0.01)。
- GLP-1RAs使用与较低死亡率相关(HR 0.525,95%CI 0.512-0.538)。
- GLP-1RAs使用与较低缺血性卒中风险相关(HR 0.871,95%CI 0.843-0.901)。
临床怎么用
- 在2型糖尿病患者中,使用GLP-1RAs可能有助于降低非创伤性脑出血风险,但需前瞻性研究确认。
局限性
- 本研究为回顾性队列研究,需前瞻性研究和未来试验确认GLP-1RAs对小血管破裂的潜在保护作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: GLP-1RAs (glucagon-like peptide-1 receptor agonists) have consistently demonstrated a protective effect against ischemic stroke. However, whether this benefit also extends to nontraumatic intracerebral hemorrhage (ICH) remains unknown. Given the blood pressure-lowering and anti-inflammatory properties of GLP-1RAs, we aimed to evaluate their potential impact on ICH risk in patients with type 2 diabetes. METHODS: We conducted a retrospective cohort study using global health care data from the TriNetX network. Patients with type 2 diabetes who used GLP-1RAs (n=326 777) were compared with those who did not (n=643 614). Propensity score matching (1:1) was performed to balance baseline characteristics, and follow-up was conducted for up to 4 years. The primary outcomes included all-cause mortality, ischemic stroke, and ICH (overall and by location). Hazard ratios and 95% CIs were calculated to assess the mean treatment effect in the treated group. RESULTS: After propensity score matching (resulting in 2 balanced groups of 255 460 individuals each), GLP-1RAs use was associated with a lower risk of ICH (hazard ratio, 0.743 [95% CI, 0.684-0.807]). The lower ICH risk associated with GLP-1RAs was observed across all ICH locations (all P≤0.01). In addition, exposure to GLP-1RAs was associated with a significantly lower rate of mortality (hazard ratio, 0.525 [95% CI, 0.512-0.538]) and ischemic stroke (hazard ratio, 0.871 [95% CI, 0.843-0.901]). CONCLUSIONS: This study highlights a novel potential association between GLP-1RAs and a lower risk of ICH in patients with type 2 diabetes. Prospective studies and future trials are needed to confirm the potential protective effect of GLP-1RAs on small vessel rupture.
引用
- Pasi M, Bretonnière A, Lochon L, et al. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Nontraumatic Intracerebral Hemorrhage in Patients With Type 2 Diabetes. Stroke. 2025. PMID: 40469023. doi:10.1161/STROKEAHA.125.050972
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。